Details of Disease

Disease Name

Transthyretin familial amyloid cardiomyopathy

Disease Class

5D00: Amyloidosis

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DISQ4327: Transthyretin familial amyloid cardiomyopathy

ICD-11

ICD-11: 5D00.20

ICD-10

ICD-10: E85.1

Expand ICD-11

'5D00.20

Expand ICD-10

'E85.1

General Information of Disease (ID: DISQ4327)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Patisiran	DMWSA0V	Approved	siRNA drug	[1]
Tafamidis meglumine	DMXRK1D	Approved	Small molecular drug	[2]
Vutrisiran	DMM1Z9G	Approved	Small interfering RNA	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ALN-TTR01	DMCSEUY	Phase 1	Antisense oligonucleotide	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	ClinicalTrials.gov (NCT01960348) APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT01994889) Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT03759379) HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT01148953) Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis. U.S. National Institutes of Health.